Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

113

Participants

Timeline

Start Date

June 30, 2004

Primary Completion Date

May 31, 2011

Conditions
Brenner TumorFallopian Tube CancerOvarian Clear Cell CystadenocarcinomaOvarian Endometrioid AdenocarcinomaOvarian Mixed Epithelial CarcinomaOvarian Mucinous CystadenocarcinomaOvarian Serous CystadenocarcinomaOvarian Undifferentiated AdenocarcinomaPrimary Peritoneal Cavity CancerStage II Ovarian Epithelial CancerStage III Ovarian Epithelial CancerStage IV Ovarian Epithelial Cancer
Interventions
PROCEDURE

adjuvant therapy

DRUG

paclitaxel

Given IV

DRUG

carboplatin

Given intraperitoneally

BIOLOGICAL

bevacizumab

Given IV

Trial Locations (19)

19103

Gynecologic Oncology Group, Philadelphia

19111

Fox Chase Cancer Center, Philadelphia

21287

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

27157

Wake Forest University Health Sciences, Winston-Salem

43214

Riverside Methodist Hospital, Columbus

52242

University of Iowa Hospitals and Clinics, Iowa City

60637

University of Chicago, Chicago

74104

Cancer Care Associates-Midtown, Tulsa

74146

Tulsa Cancer Institute, Tulsa

77030

M D Anderson Cancer Center, Houston

92868

University of California Medical Center At Irvine-Orange Campus, Orange

98104

Pacific Gynecology Specialists, Seattle

98109

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle

Seattle Cancer Care Alliance, Seattle

98195

University of Washington Medical Center, Seattle

08103

Cooper Hospital University Medical Center, Camden

02905

Women and Infants Hospital, Providence

701-0192

Kawasaki Medical School, Okayama-Ken

350-1298

Saitama Medical University International Medical Center, Saitama

All Listed Sponsors
collaborator

Gynecologic Oncology Group

NETWORK

lead

National Cancer Institute (NCI)

NIH

NCT00079430 - Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | Biotech Hunter | Biotech Hunter